FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D).C. 2	20549
---------------	--------	-------

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Transaction(s) (Instr. 3 and 4)

Ownership (Instr. 4)

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Addres		Person*		r Name and Ticker Life Science	0 ,		(Check	tionship of Reportin all applicable) Director Officer (give title	10% (
(Last) C/O WAVE LIF		(Middle)	3. Date 05/30/	of Earliest Transac 2018	tion (Month/D	ay/Year)	X	below)	below emarks	
(Street) CAMBRIDGE (City)	MA (State)	02138 (Zip)	4. If Am	endment, Date of (Original Filed (Month/Day/Year)	6. Indiv Line) X	idual or Joint/Group Form filed by One Form filed by Mor Person	Reporting Pers	on
		Table I - Nor	n-Derivative S	ecurities Acqu	iired, Disp	osed of, or Benefi	cially	Owned		
Date			2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)		5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership

05/30/2018 $M^{(1)}$ 46,573 24,496 A \$2.48 D S⁽¹⁾ 05/30/2018 24,496 D \$45.5 22,077 D **M**⁽¹⁾ 06/01/2018 24,496 A \$2.48 46,573 D **S**⁽¹⁾ 06/01/2018 24,496 D \$48 22,077 D

Amount

(A) or (D)

Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

ν

Code

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of E		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Share Option (right to buy)	\$2.48	05/30/2018		M ⁽¹⁾			24,496	(2)	03/10/2025	Ordinary Shares	24,496	\$0.00	101,564	D	
Share Option (right to buy)	\$2.48	06/01/2018		M ⁽¹⁾			24,496	(2)	03/10/2025	Ordinary Shares	24,496	\$0.00	77,068	D	

Explanation of Responses:

Ordinary Shares

Ordinary Shares

Ordinary Shares

Ordinary Shares

1. The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018.

2. The share option represented a right to purchase a total of 126,174 ordinary shares, 25% of which became exercisable on April 15, 2015, and the remaining shares vest in 36 equal monthly installments thereafter.

Remarks:

SVP, Corporate Development, Head of Emerging Areas

06/01/2018 /s/ Chris Francis

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.